UPDATED: MHRA guidance on coronavirus (COVID-19)

Image of a form with ticks to show MHRA guidance on coronavirus (COVID-19)

The MHRA is producing guidance on coronavirus (COVID-19) for industry. The Medicines and Healthcare products Regulatory Agency (MHRA) is working closely with Department of Health and Social Care and other healthcare partners on COVID-19.

They are prioritising work including:

  • Supporting and authorising the development of vaccines
  • Clinical trials of new medicines
  • Managing the supply of medicines and healthcare products.

They are also providing information to patients, manufacturers and healthcare professionals through their established information channels and alert systems.

The National Institute for Biological Standards and Control (NIBSC), part of the MHRA, also plays a major role in assuring the quality of biological medicines, worldwide.

The MHRA Inspectorate blog has several posts covering the approach taken on clinical trials and advice on other areas like remote working.

The British Pharmacopoeia has published a statement on its products and services during the outbreak, including some actions for any British Pharmacopoeia Chemical Reference Substance (BPCRS) customers who are ordering any substances classified as controlled drugs or precursor chemicals.

Inspections and good practice

Regulatory flexibilities


Keep up to date with our news on COVID-19 and coronavirus.